Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Recruiting Phase 2Phase 3 Interventional

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

NCT07881120
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Interventions
Afimetoran, Placebo
Drug
Lead sponsor
Beeline Medicines Corporation
Industry
Eligibility
16 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • DeBary, Florida • Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients

NCT00664703
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Lobeline sulfate, Methylphenidate HCl, Placebo
Drug
Lead sponsor
Yaupon Therapeutics
Industry
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 31, 2026, 5:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of Sex in the Effect of Dietary Capsaicin on Cardiovascular Health

NCT06363305
View directory record Official record
Conditions
Pre Hypertension, Hypertension
Interventions
Dietary capsules
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

NCT00549770
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Acute Bipolar Mania

NCT00097266
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Aripiprazole, Haloperidol
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

NCT01273064
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, pegylated interferon, Ribavirin, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 31, 2026, 5:15 PM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis

NCT01450709
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Kibow Biotics
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX7353 capsules, Placebo oral capsule
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01474330
View directory record Official record
Conditions
Healthy
Interventions
Pomalidomide, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Hydroxycitrate on Urine Chemistry

NCT03348228
View directory record Official record
Conditions
Nephrolithiasis
Interventions
Hydroxycitrate (HCA)
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

NCT03608371
View directory record Official record
Conditions
Parkinson Disease, Motor Disorder
Interventions
BTRX-246040, Placebo
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
30 Years to 76 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Hallandale, Florida • Farmington Hills, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination

NCT04951336
View directory record Official record
Conditions
COVID-19 Vaccination
Interventions
FoTv
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

NCT04910165
View directory record Official record
Conditions
Arthritis Knee, Pain, Postoperative, Opioid Use
Interventions
Exparel, Ropivacaine
Drug
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

NCT00556075
View directory record Official record
Conditions
Endometriosis
Interventions
Proellex 25 mg, Placebo, Proellex 50 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

NCT04102501
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
RT001, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
12 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

NCT04706091
View directory record Official record
Conditions
Restless Legs Syndrome, Insomnia, Sleep Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania

NCT00488618
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Cariprazine (RGH-188), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

NCT01463397
View directory record Official record
Conditions
Neuropathic Pain
Interventions
SAR292833, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • Garden Grove, California • Newport Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 4 Interventional Results available

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

NCT00337350
View directory record Official record
Conditions
Schizophrenia
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

NCT00890890
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Avagacestat, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
45 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

NCT01592747
View directory record Official record
Conditions
Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl), Placebo capsules
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
64
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 31, 2026, 5:15 PM EDT